Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HSK 3486

Drug Profile

HSK 3486

Alternative Names: HSK-3486

Latest Information Update: 18 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Haisco Pharmaceutical
  • Class Cyclopropanes; General anaesthetics; Phenols
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anaesthesia

Most Recent Events

  • 18 Dec 2019 Sichuan Haisco Pharmaceutical Group plans a phase I trial in Healthy volunteers in China in December 2019 (NCT04197661)
  • 06 Nov 2019 Sichuan Haisco Pharmaceutical Group initiates a phase I trial in Healthy volunteers in China (IV) (NCT04145596)
  • 04 Nov 2019 Sichuan Haisco Pharmaceutical plans a phase-II trial for Sedation (IV, Injection) in December 2019 (NCT04147416)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top